Australian Biotech Hookipa is about to raise a 75M € IPO on Nasdaq for their counter viral and cancer vaccines

The Austrian biotech Hookipa expects to raise €75M ($84M) in an IPO on the Nasdaq stock exchange to fund the phase II development of a vaccine for the virus cytomegalovirus, and the first clinical trials of its cancer vaccines.


Leave a Reply

Your email address will not be published. Required fields are marked *